Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease

Pathologie Biologie

Volumn 62, Issue 6, 2014, Pages 333-336

  El Kadmiri, N ^a,c   Slassi, I ^a,b   El Moutawakil, B ^a,b   Nadifi, S ^a   Tadevosyan, A ^e   Hachem, A ^d   Soukri, A ^c  

^a HASSAN II UNIVERSITY   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^c Université HASSAN II   (Morocco)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alzheimer's disease; GAPDH; Neurofibrillary tangles; amyloid aggregation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; BIOLOGICAL MARKER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; MAPT PROTEIN, HUMAN; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; APOPTOSIS; BINDING AFFINITY; CELL MEDIATED CYTOTOXICITY; ENZYME LOCALIZATION; ENZYME MODIFICATION; ENZYME STRUCTURE; HUMAN; MOLECULAR MECHANICS; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; PROTEIN AGGREGATES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TAU PROTEINS;

EID: 84908327030     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.08.002     Document Type: Review

References (55)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Neurol Central 1906, 25:1134.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
4. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10:698-712.
5. Higgins G.A., Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav Pharmacol 2003, 14:419-438.
6. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002, 36:1307-1313.
7. Swomley A.M., Forster S., Keeney J.T., Triplett J., Zhang Z., Sultana R., et al. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 2013.
8. Furgerson M., Fechheimer M., Furukawa R. Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain. PloS One 2012, 7:e44996.
9. Lee H.P., Zhu X., Casadesus G., Castellani R.J., Nunomura A., Smith M.A., et al. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 2010, 10:1201-1208.
10. Caudle W.M., Pan S., Shi M., Quinn T., Hoekstra J., Beyer R.P., et al. Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl 2008, 2:1484-1497.
11. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Gen 2007, 39:17-23.
12. Sunaga K., Takahashi H., Chuang D.M., Ishitani R. Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci Lett 1995, 200:133-136.
13. Butterfield D.A., Hardas S.S., Lange M.L. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimer's Dis 2010, 20:369-393.
14. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002, 32:1050-1060.
15. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009, 7:65-74.
16. Newman S.F., Sultana R., Perluigi M., Coccia R., Cai J., Pierce W.M., et al. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res 2007, 85:1506-1514.
17. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006, 22:76-87.
18. Seidler N.W. Basic biology of GAPDH. Adv Exp Med Biol 2013, 985:1-36.
19. Jenkins J.L., Tanner J.J. High-resolution structure of human D-glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr 2006, 62:290-301.
20. Sirover M.A. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999, 1432:159-184.
21. Demarse N.A., Ponnusamy S., Spicer E.K., Apohan E., Baatz J.E., Ogretmen B., et al. Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation. J Mol Biol 2009, 394:789-803.
22. Kondo S., Kubota S., Mukudai Y., Nishida T., Yoshihama Y., Shirota T., et al. Binding of glyceraldehyde-3-phosphate dehydrogenase to the cis-acting element of structure-anchored repression in ccn2 mRNA. Biochem Biophys Res Commun 2011, 405:382-387.
23. Zheng L., Roeder R.G., Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003, 114:255-266.
24. Tisdale E.J. Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota/lambda and plays a role in microtubule dynamics in the early secretory pathway. J Biol Chem 2002, 277:3334-3341.
25. Bryksin A.V., Laktionov P.P. Role of glyceraldehyde-3-phosphate dehydrogenase in vesicular transport from golgi apparatus to endoplasmic reticulum. Biochem Biokhim 2008, 73:619-625.
26. Patterson R.L., van Rossum D.B., Kaplin A.I., Barrow R.K., Snyder S.H. Inositol 1,4,5-trisphosphate receptor/GAPDH complex augments Ca2+ release via locally derived NADH. Proc Natl Acad Sci USA 2005, 102:1357-1359.
27. Sioud M., Jespersen L. Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase. J Mol Biol 1996, 257:775-789.
28. Puder M., Soberman R.J. Glutathione conjugates recognize the Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1997, 272:10936-10940.
29. Chen R.W., Saunders P.A., Wei H., Li Z., Seth P., Chuang D.M. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J Neurosci 1999, 19:9654-9662.
30. Hara M.R., Snyder S.H. Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol Neurobiol 2006, 26:527-538.
31. Hara M.R., Cascio M.B., Sawa A. GAPDH as a sensor of NO stress. Biochim Biophys Acta 2006, 1762:502-509.
32. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson V.L., et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 2006, 103:3887-3889.
33. Bae B.I., Hara M.R., Cascio M.B., Wellington C.L., Hayden M.R., Ross C.A., et al. Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci USA 2006, 103:3405-3409.
34. Burke J.R., Enghild J.J., Martin M.E., Jou Y.S., Myers R.M., Roses A.D., et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996, 2:347-350.
35. Verdier Y., Foldi I., Sergeant N., Fulop L., Penke Z., Janaky T., et al. Characterization of the interaction between Abeta 1-42 and glyceraldehyde phosphodehydrogenase. J Pept Sci 2008, 14:755-762.
36. Cumming R.C., Schubert D. Amyloid beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. FASEB J 2005, 19:2060-2062.
37. Schulze H., Schuler A., Stuber D., Dobeli H., Langen H., Huber G. Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's beta-amyloid precursor protein. J Neurochem 1993, 60:1915-1922.
38. Torres-Bugeau C.M., Avila C.L., Raisman-Vozari R., Papy-Garcia D., Itri R., Barbosa L.R., et al. Characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase early amyloid-like oligomers and their implication in alpha-synuclein aggregation. J Biol Chem 2012, 287:2398-2409.
39. Tamaoka A., Endoh R., Shoji S., Takahashi H., Hirokawa K., Teplow D.B., et al. Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Neurobiol Aging 1996, 17:405-414.
40. Nakamura S., Tamaoka A., Sawamura N., Shoji S., Nakayama H., Ono F., et al. Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys. Neurosci Lett 1995, 201:151-154.
41. Oyama R., Yamamoto H., Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 2000, 1479:91-102.
42. Verdier Y., Huszar E., Penke B., Penke Z., Woffendin G., Scigelova M., et al. Identification of synaptic plasma membrane proteins co-precipitated with fibrillar beta-amyloid peptide. J Neurochem 2005, 94:617-628.
43. Naletova I., Schmalhausen E., Kharitonov A., Katrukha A., Saso L., Caprioli A., et al. Non-native glyceraldehyde-3-phosphate dehydrogenase can be an intrinsic component of amyloid structures. Biochim Biophys Acta 2008, 1784:2052-2058.
44. Mazzola J.L., Sirover M.A. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem 2001, 76:442-449.
45. Kornberg M.D., Sen N., Hara M.R., Juluri K.R., Nguyen J.V., Snowman A.M., et al. GAPDH mediates nitrosylation of nuclear proteins. Nat cell Biol 2010, 12:1094-1100.
46. Colell A., Green D.R., Ricci J.E. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 2009, 16:1573-1581.
47. Nakajima H., Amano W., Fujita A., Fukuhara A., Azuma Y.T., Hata F., et al. The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress induced aggregation and cell death. J Biol Chem 2007, 282:26562-26574.
48. Iqbal K., Alonso Adel C., Chen S., Chohan M.O., El-Akkad E., Gong C.X., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
49. Higuchi M., Zhang B., Forman M.S., Yoshiyama Y., Trojanowski J.Q., Lee V.M. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci 2005, 25:9434-9443.
50. Lee V.M., Kenyon T.K., Trojanowski J.Q. Transgenic animal models of tauopathies. Biochim Biophys Acta 2005, 1739:251-259.
51. Wang Q., Woltjer R.L., Cimino P.J., Pan C., Montine K.S., Zhang J., et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 2005, 19:869-871.
52. Yang G., Wang L., Zhu M., Xu D. Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis. Neurol Res 2008, 30:613-622.
53. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998, 64:298-305.
54. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F., et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001, 22:77-78.
55. Andreasen N., Blennow K. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 2002, 23:1205-1214.